Mersana Therapeutics Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Mersana Therapeutics Inc 's ROA in the third quarter of 2025?
Mersana Therapeutics Inc recorded a cumulative net loss of $-70 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -71.29%.

However, within the Healthcare sector 663 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2025 from 4157 to 4201.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	-62.94 %	-52.78 %	-43.29 %	-35.68 %	-35.4 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-70	-74	-74	-69	-75
Return On Assets (TTM)	-71.29 %	-59.61 %	-50.29 %	-41.19 %	-39.79 %
MRSN's Total Ranking	# 4201	# 4157	# 4136	# 4659	# 4091
Total Assets (TTM) in million	61	82	109	141	165
Seq. Total Assets Change	-25.75 %	-24.77 %	-22.51 %	-14.37 %	-5.41 %
Seq. Net Income Change	-	-	-	-	-

MRSN's 5 Years Annual ROA >> Back to MRSN Management Effectiveness >> Compare MRSN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 304
Sector	# 664
Overall	# 4155

Return On Assets Statistics
High	Average	Low
3.73 %	-51.05 %	-83.03 %
(Dec 31 2019)		(Jun 30 2022)

Financial Statements
Mersana Therapeutics Inc 's Assets	$ 61 million	MRSN's Balance sheet
Mersana Therapeutics Inc 's Income	$ -8 million	Quarterly MRSN's Income Statement
MRSN's Income by Division		See MRSN's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-35.68 %	-32.64 %	66.03 %	-25.9 %	150.55 %
Total Assets in million	141	219	325	196	264
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-69	-172	-204	-170	-88
Annual Return On Assets	-49.11 %	-78.37 %	-62.8 %	-86.82 %	-33.31 %

MRSN's 5 Years Annual ROA >> Back to MRSN Management Effectiveness >> Compare MRSN ROA to its Competitors

More Return On Assets Ratios
MRSN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MRSN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MRSN's Competitors
Subscribers only: Roa for Mersana Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for MRSN's Customers

You may also want to know
MRSN's Roi	MRSN's Inventory Turnover Ratio	MRSN's Growth Rates	MRSN's Dividend Comparisons
	MRSN's Profitability Ratios	MRSN's Asset Turnover Ratio	MRSN's Dividend Growth
MRSN's Roe	MRSN's Valuation Ratios	MRSN's Financial Strength Ratios	MRSN's Dividend Payout Ratio

Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector

ROA

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.